Allovir Inc
NASDAQ:ALVR
Allovir Inc
NASDAQ:ALVR
Price:
11.47
USD
16.92%
Market Closed
Market Cap:
$35.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Allovir Inc
NASDAQ:ALVR
|
US |
|
P
|
Pearson PLC
NYSE:PSO
|
UK |
|
Re/Max Holdings Inc
NYSE:RMAX
|
US |
|
Bumi Serpong Damai Tbk PT
OTC:BSPDY
|
ID |
|
L
|
Leeds Group PLC
LSE:LDSG
|
UK |
Balance Sheet
Balance Sheet Decomposition
Allovir Inc
Allovir Inc
Balance Sheet Decomposition is not available for
Allovir Inc
Allovir Inc
Balance Sheet
Allovir Inc
Allovir Inc
Currency: USD
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
22
|
61
|
123
|
202
|
106
|
90
|
118
|
|
| Cash Equivalents |
22
|
61
|
123
|
202
|
106
|
90
|
118
|
|
| Short-Term Investments |
0
|
65
|
234
|
47
|
128
|
94
|
0
|
|
| Total Receivables |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
3
|
1
|
5
|
5
|
9
|
3
|
0
|
|
| Total Current Assets |
25
|
127
|
361
|
253
|
243
|
188
|
119
|
|
| PP&E Net |
0
|
12
|
10
|
31
|
33
|
2
|
0
|
|
| PP&E Gross |
0
|
12
|
10
|
31
|
33
|
2
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
2
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
2
|
2
|
1
|
0
|
|
| Total Assets |
25
N/A
|
139
+451%
|
371
+166%
|
287
-23%
|
277
-3%
|
191
-31%
|
119
-38%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
1
|
1
|
8
|
3
|
7
|
0
|
|
| Accrued Liabilities |
1
|
8
|
11
|
27
|
21
|
21
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
3
|
0
|
1
|
3
|
0
|
1
|
0
|
|
| Total Current Liabilities |
4
|
9
|
12
|
38
|
24
|
28
|
5
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
9
|
6
|
24
|
28
|
17
|
0
|
|
| Total Liabilities |
4
N/A
|
18
+381%
|
18
N/A
|
61
+244%
|
53
-14%
|
45
-14%
|
5
-88%
|
|
| Equity | ||||||||
| Common Stock |
52
|
173
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
32
|
55
|
125
|
297
|
466
|
656
|
715
|
|
| Additional Paid In Capital |
1
|
4
|
478
|
523
|
691
|
802
|
828
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Equity |
22
N/A
|
122
+463%
|
353
+190%
|
225
-36%
|
225
0%
|
146
-35%
|
113
-22%
|
|
| Total Liabilities & Equity |
25
N/A
|
139
+451%
|
371
+166%
|
287
-23%
|
277
-3%
|
191
-31%
|
119
-38%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
69
|
69
|
62
|
64
|
93
|
114
|
5
|
|
Switch to:
Switch to:
See Also
Discover More
